Subretinal Fluid (SRF) in the Eye: Causes & Treatment

Subretinal fluid is a buildup of liquid between the retina’s light-sensing photoreceptor cells and the layer of tissue just behind them called the retinal pigment epithelium (RPE). Normally the RPE acts as a pump, actively moving fluid out of this space and into the blood supply behind the eye. When that pump fails or gets overwhelmed, fluid collects, lifts the retina away from its nutrient source, and can blur or distort vision. The causes range from age-related macular degeneration and diabetic eye disease to steroid medications and even tumors, and the treatment depends almost entirely on what drove the fluid there in the first place.

How the Eye Normally Keeps Fluid Out

The retina sits on top of the RPE like wallpaper glued to a wall, and the “glue” is partly mechanical and partly hydraulic. The RPE forms a tight seal known as the outer blood-retinal barrier, which controls what passes between the choroidal blood vessels behind the eye and the retina itself. One of the RPE’s key jobs is to pump fluid from the subretinal space outward toward the choroid, preventing any accumulation that would peel the retina away from its support.¹ When this pumping mechanism is healthy, tiny amounts of fluid that naturally seep through are cleared before they can pool. Trouble starts when the barrier leaks faster than the pump can compensate, or when the pump itself breaks down.

Central Serous Chorioretinopathy

Central serous chorioretinopathy (CSCR, often shortened to CSC) is one of the most common reasons subretinal fluid appears in otherwise healthy-looking eyes. It typically strikes adults between their 30s and 50s, more often men, and the hallmark symptom is a blurry or dim spot in the center of vision, sometimes with straight lines appearing warped. The underlying problem involves the choroidal blood vessels becoming abnormally permeable, allowing fluid to push through the RPE and collect beneath the retina.

Corticosteroids are a well-established trigger. In one reported case, a 24-year-old man developed central serous retinopathy in his right eye just three days after starting oral prednisolone for facial nerve palsy; his vision improved within a week of tapering the drug.² The steroid connection is so strong that any form of corticosteroid, including inhaled, topical skin creams, and joint injections, has been implicated. Stress-related elevations in endogenous cortisol are thought to play a role too, though the relationship between the eye’s own steroid environment and CSCR turns out to be counterintuitive: one study found that cortisol levels inside the eyes of CSCR patients were actually lower than in control eyes, while certain steroid-metabolism ratios were altered, suggesting the problem may involve how the eye processes steroids locally rather than simply having too much cortisol.³

Most acute episodes resolve on their own within a few months, but chronic CSCR, where fluid lingers for more than about three to four months or keeps recurring, is a different animal. Left untreated, it can damage the photoreceptors permanently.

Age-Related Macular Degeneration

In wet (neovascular) age-related macular degeneration, abnormal new blood vessels grow from the choroid underneath or into the retina. These vessels are fragile and leaky, and the fluid they release is a major source of subretinal and intraretinal fluid.⁴ Vascular endothelial growth factor (VEGF) is a key driver of this abnormal vessel growth, which is why anti-VEGF injections have become the cornerstone treatment.⁵

The relationship between subretinal fluid and vision in AMD is more nuanced than you might expect. While intraretinal fluid (fluid trapped within the retina’s own layers) is clearly bad for vision, a moderate amount of subretinal fluid may actually be tolerable or even protective. Current evidence suggests that subretinal fluid up to roughly 150 to 200 micrometers thick can persist with minimal impact on visual acuity, and that its presence may slow the development of macular atrophy and fibrosis.⁶ This has practical implications for how aggressively doctors pursue complete fluid elimination in AMD patients, a point we’ll return to in the treatment section.

Diabetic Macular Edema and Other Causes

Diabetes can also cause subretinal fluid, though it more commonly produces swelling within the retina itself. In diabetic macular edema, chronic high blood sugar damages both the inner and outer blood-retinal barriers, allowing proteins and fluid to leak into spaces where they don’t belong.⁷ Research has linked the presence of subretinal fluid in diabetic eyes to activation of immune cells called microglia in the outer retina, which appears to contribute to RPE dysfunction and barrier breakdown.⁸

Rhegmatogenous retinal detachment is another major context for subretinal fluid, though the mechanism is different. Here, a tear or hole in the retina allows the gel-like vitreous inside the eye to seep beneath the retina, physically peeling it away. This is a surgical emergency, and removing or draining the subretinal fluid during repair surgery is often part of the procedure.

Less common causes include choroidal tumors. Both choroidal melanomas and metastatic tumors to the eye can produce subretinal exudation as one of their first clinical signs.⁹ Inflammatory conditions such as Vogt-Koyanagi-Harada disease, where the immune system attacks pigmented cells in the eye, can also drive substantial subretinal fluid accumulation. Because the treatment for each underlying cause is so different, identifying why the fluid is there matters as much as identifying the fluid itself.

How Subretinal Fluid Is Diagnosed

Optical coherence tomography (OCT) is the workhorse diagnostic tool. It uses light waves to create cross-sectional images of the retina with micrometer-level resolution, allowing clinicians to see exactly where fluid is sitting, how thick it is, and whether it’s beneath the retina, within the retina, or both.¹⁰ That distinction between subretinal and intraretinal fluid matters enormously for treatment decisions. In studies comparing how well treating eye doctors detected fluid versus trained reading-center graders, disagreements were more common when fluid areas were small, highlighting the challenge of catching subtle accumulations.¹¹

For suspected CSCR, indocyanine green angiography (ICGA) adds valuable information that OCT alone can’t provide. This imaging technique uses an injected dye that fluoresces under near-infrared light, making the choroidal blood vessels visible. It can reveal dilated choroidal vessels and areas of vascular hyperpermeability that point to CSCR, and it’s considered useful for a range of conditions including chronic CSCR, choroidal neovascularization, and several inflammatory eye diseases.¹² Ultrawidefield versions of ICGA can capture the entire choroidal vascular network in a single shot. In one study of CSCR patients, choroidal vascular hyperpermeability was found in every affected eye, making it effectively diagnostic for the condition.³

Fluorescein angiography, a related technique using a different dye, remains the classic way to pinpoint the exact leak site in acute CSCR. It shows the characteristic “smokestack” or “ink-blot” pattern of dye pooling beneath the retina. Between OCT for structural detail, fluorescein angiography for leak localization, and ICGA for choroidal vascular assessment, clinicians can build a thorough picture of what’s happening and why.

AI-Assisted Fluid Detection

Reading OCT scans accurately is harder than it sounds, especially when small pockets of subretinal fluid need to be distinguished from normal anatomical shadows or artifacts. This has driven interest in deep-learning algorithms that can automatically detect and measure fluid. One early deep-learning system achieved an area under the curve of 0.92 for detecting subretinal fluid, with a correlation of 0.96 between its measurements and those made by expert human graders.¹³ More recent iterations can automatically quantify fluid across different OCT device platforms.¹⁴

The practical value here is consistency. A retinal specialist might interpret a borderline scan differently on a busy Friday afternoon than they would on a quiet Tuesday morning. Algorithms don’t have that problem. They’re especially useful for longitudinal monitoring, where the question is whether a thin sliver of fluid has grown or shrunk by a few micrometers between visits. That kind of precision matters when treatment decisions hinge on whether fluid is stable or progressing.

Treatment for CSCR

Acute CSCR is often managed with observation first, since many cases resolve spontaneously within a few months. If the fluid persists or recurs, active treatment is warranted. Photodynamic therapy (PDT) has become a frontline option. It involves injecting a light-sensitive drug called verteporfin into the bloodstream and then activating it with a low-energy laser aimed at the leaky choroidal area. The activated drug seals off the abnormal vessels without damaging the overlying retina.¹⁵

To reduce the risk of side effects, clinicians commonly use reduced-intensity protocols. A comparison of half-fluence (lower laser energy) versus half-dose (less verteporfin drug) PDT found that half-dose treatment produced faster fluid clearance: complete resolution in about 86% of eyes at one month, compared with about 61% for half-fluence. By twelve months, half-dose PDT achieved complete resolution in all treated eyes.¹⁶ Another study of half-dose PDT reported that fluid resolved completely in over 96% of eyes within a year.¹⁷

Selective retina therapy (SRT), a newer laser approach, targets the RPE cells specifically while sparing the photoreceptors above them. In a study of Korean patients with acute CSCR, subretinal fluid resolved in all 16 treated eyes within three months, with significant improvements in both visual acuity and central retinal thickness and no laser-related complications.¹⁸ SRT is still less widely available than PDT but represents a promising direction.

Mineralocorticoid Receptor Antagonists for CSCR

Because of the steroid-metabolism link in CSCR, drugs that block mineralocorticoid receptors (MRAs) have been investigated as a medical alternative to laser therapy. The two drugs studied most are eplerenone and spironolactone, both originally developed for heart failure and blood pressure. The idea is that blocking mineralocorticoid receptors in the choroid may reduce the vascular leakiness that drives fluid accumulation.

A recent meta-analysis found that both MRAs reduced subretinal fluid height more than observation at one month, with a four-fold higher chance of complete fluid resolution in the short term. However, the picture reversed at twelve months: the observation group had lower residual fluid and a higher resolution rate, suggesting that MRAs speed up initial improvement but don’t necessarily improve long-term outcomes compared with waiting.¹⁹ Between the two drugs, spironolactone appears to edge out eplerenone. One head-to-head comparison found spironolactone was statistically superior for improving visual acuity, while both drugs performed similarly in promoting fluid reabsorption.²⁰ A separate meta-analysis confirmed spironolactone’s advantage for both visual acuity and fluid-height reduction over placebo, while eplerenone improved acuity modestly but had no significant effect on fluid height.²¹

The practical takeaway is that MRAs can offer symptom relief and buy time, but they’re not a definitive cure for chronic CSCR. PDT remains the stronger option when the fluid needs to be eliminated decisively.

Anti-VEGF Therapy for Wet AMD

For subretinal fluid caused by wet AMD, anti-VEGF injections are the standard of care. Drugs like ranibizumab, aflibercept, and bevacizumab are injected directly into the eye to block the growth factor that drives abnormal blood-vessel formation and leakage. These injections have transformed wet AMD from a near-certain path to legal blindness into a manageable chronic condition for most patients, though they typically require ongoing monthly or bimonthly treatments.

Here’s where the question of “how dry should the retina be?” becomes clinically meaningful. Data from ranibizumab-treated patients showed that eyes with residual subretinal fluid (but no intraretinal fluid) actually gained more vision letters than eyes where all fluid had been completely cleared. Eyes with residual subretinal fluid alone gained an average of about 14 letters at twelve months, while eyes with completely resolved fluid gained about 11 letters.²² The worst outcomes belonged to eyes with residual intraretinal fluid, which gained the fewest letters. This pattern has led some experts to suggest that tolerating a thin layer of subretinal fluid, rather than chasing its complete elimination with more frequent injections, may produce better visual and structural results in AMD.⁶

That doesn’t mean subretinal fluid in AMD is harmless across the board. Large or rapidly accumulating fluid still warrants aggressive treatment. The “tolerant” approach applies specifically to small, stable amounts, and making that judgment call requires regular OCT monitoring.

Surgical Drainage During Retinal Detachment Repair

When subretinal fluid accumulates from a retinal tear or detachment, the treatment is surgical. Vitrectomy, where the vitreous gel is removed and the retina is repositioned, often involves draining the subretinal fluid as part of the procedure. But how much fluid needs to come out during surgery has been debated.

One prospective study found that partial drainage produced anatomical and visual outcomes comparable to complete drainage in cases where the macula had already detached, suggesting that surgeons don’t always need to chase every last drop of fluid from beneath the retina.²³ The technique used for drainage matters, though. A study comparing different approaches found that draining through the pre-existing retinal break produced the best overall outcomes, while using heavy liquid (perfluorocarbon) to push fluid out was associated with worse visual acuity and a greater risk of outer-retinal damage and swelling.²⁴ Another comparison found that while perfluorocarbon-assisted drainage through the existing break and posterior retinotomy gave similar anatomical success rates, patients who had drainage through the break reported less visual distortion afterward.²⁵

Even after successful detachment surgery, subretinal fluid can linger beneath the macula for weeks or months. This persistent submacular fluid is associated with disruption of the photoreceptor layer and can limit the visual recovery a patient achieves.²⁶

When Subretinal Fluid Damages the Photoreceptors

The longer subretinal fluid sits beneath the fovea (the central point of sharpest vision), the greater the risk of permanent photoreceptor damage. In CSCR, a study examining the foveal photoreceptor layer found that when symptoms had been present for less than a year, the outer photoreceptor layer was preserved in nearly all cases. But when symptoms had persisted for over a year, the photoreceptor layer was atrophic in roughly half of eyes examined.²⁷ This finding underscores a practical rule of thumb: CSCR that hasn’t resolved on its own within three to four months deserves active treatment to prevent crossing into the danger zone where photoreceptor loss becomes irreversible.

The mechanism of damage involves both nutrient deprivation and mechanical separation. Photoreceptors depend on the RPE for metabolic support, including recycling visual pigment and supplying oxygen and glucose. When fluid lifts the retina away from the RPE, that supply line is disrupted. Over time, the outer segments of the photoreceptors shorten, disorganize, and eventually disappear entirely. Even if the fluid resolves after that point, the lost photoreceptors don’t regenerate, and vision loss becomes permanent.

Choroidal Tumors as a Hidden Cause

Subretinal fluid doesn’t always point to a vascular or degenerative disease. Choroidal melanoma, the most common primary eye cancer in adults, can produce subretinal exudation as one of its earliest signs, sometimes before the tumor itself is obvious on clinical exam.⁹ Metastatic cancers that spread to the choroid from other organs can do the same.²⁸ The fluid in these cases results from the tumor disrupting the overlying RPE and choroidal vasculature. Clinicians examining unexplained subretinal fluid, especially if it doesn’t fit the typical CSCR or AMD pattern, will usually order a thorough dilated exam and possibly ultrasonography to rule out a mass lurking beneath the retina. Catching a choroidal tumor early can be life-saving, not just sight-saving.